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Abstract
Coronavirus sub- genomic mRNA (sgmRNA) synthesis occurs via a process of discontinuous transcription involving comple-
mentary transcription regulatory sequences (TRSs), one (TRS- L) encompassing the leader sequence of the 5′ untranslated 
region (UTR), and the other upstream of each structural and accessory gene (TRS- B). Several coronaviruses have an ORF 
located between the N gene and the 3′-UTR, an area previously thought to be non- coding in the Gammacoronavirus infectious 
bronchitis virus (IBV) due to a lack of a canonical TRS- B. Here, we identify a non- canonical TRS- B allowing for a novel sgmRNA 
relating to this ORF to be produced in several strains of IBV: Beaudette, CR88, H120, D1466, Italy-02 and QX. Interestingly, the 
potential protein produced by this ORF is prematurely truncated in the Beaudette strain. A single nucleotide deletion was made 
in the Beaudette strain allowing for the generation of a recombinant IBV (rIBV) that had the potential to express a full- length 
protein. Assessment of this rIBV in vitro demonstrated that restoration of the full- length potential protein had no effect on 
viral replication. Further assessment of the Beaudette- derived RNA identified a second non- canonically transcribed sgmRNA 
located within gene 2. Deep sequencing analysis of allantoic fluid from Beaudette- infected embryonated eggs confirmed the 
presence of both the newly identified non- canonically transcribed sgmRNAs and highlighted the potential for further yet uni-
dentified sgmRNAs. This HiSeq data, alongside the confirmation of non- canonically transcribed sgmRNAs, indicates the poten-
tial of the coronavirus genome to encode a larger repertoire of genes than has currently been identified.
INTRODUCTION
Coronaviruses are members of the order Nidovirales, and 
possess the largest genomes of the currently identified RNA 
viruses. There are four genera, Alpha-, Beta-, Gamma- and 
Deltacoronavirus, all of which contain coronaviruses that 
pose a significant threat to human health, animal health 
and welfare, as well as food security. Notable members of 
the genus Betacoronavirus include the human pathogens 
severe acute respiratory syndrome coronavirus (SARS-
 CoV) and Middle East respiratory syndrome coronavirus 
(MERS- CoV), and the recent zoonotic virus SARS- CoV-2, 
the causative agent of COVID-19. Infectious bronchitis virus 
(IBV), the prototype of the genus Gammacoronavirus, is the 
aetiological agent of infectious bronchitis; an acute, highly 
contagious and economically important disease of poultry 
(reviewed elsewhere [1, 2]). As with all members of the family 
Coronaviridae, IBV possesses a large, ~27 kb, non- segmented, 
positive- sense, ssRNA genome, which is capped at the 5′ 
end and polyadenylated at the 3′ end [3]. General genome 
organization is shared between all coronaviruses, with the 5′ 
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proximal two- thirds of the genome encoding 16 or, in the case 
of IBV, 15 non- structural proteins (nsps) as part of two large 
polyproteins, 1a and 1ab, with the latter produced as a result 
of a −1 frame shift [4, 5]. Preceding ORF 1a is an untranslated 
region (UTR) referred to as the 5′-UTR. The 3′ proximal end 
of the genome encodes the structural proteins in the order of 
spike (S), envelope (E), membrane (M) and nucleocapsid (N), 
followed by another UTR, the 3′-UTR. Interspersed within 
the structural genes are several small non- structural genes 
referred to as accessory or group- specific genes, with the 
location and number of these genes varying between coro-
naviruses. The IBV genome contains two confirmed accessory 
genes, gene 3 comprised of ORFs 3a, 3b and 3c (E), located 
between S and M, and gene 5 comprised of ORFs 5a and 5b, 
located between M and N, encoding accessory proteins 3a 
and 3b, the E protein and 5a and 5b, respectively. Gene 3 and 
gene 5 are each expressed from a single sub- genomic mRNA 
(sgmRNA). A novel group- specific protein, 4b, has addition-
ally been proposed to be produced from a sgmRNA gener-
ated from a non- canonical transcription regulatory sequence 
(TRS), from a region of the genome previously referred to as 
the intergenic region (IR) located between gene M and gene 
5 [6, 7].
Transcription of the structural and accessory genes occurs 
via a process of discontinuous transcription during negative- 
strand synthesis; a model unique to the members of the order 
Nidovirales, and first proposed by Sawicki and Sawicki in 1995 
[8]. The model relies on the presence of two complementary 
TRSs, one located at the 5′ end of the genome, in the leader 
sequence, part of the 5′-UTR (TRS- L), and the second 
upstream of the gene, within the body of the genome (TRS- 
B). During minus- strand sgRNA synthesis, each TRS- B may 
act as a stop signal for the transcription- replication complex 
and facilitate a template switch through hybridization to the 
TRS- L. The result of this process is a nested set of negative- 
sense sgRNAs that act as templates for the generation of 
positive- sense sgmRNAs with co- terminal 5′ and 3′ ends. 
Each sgmRNA contains a common 5′ leader sequence and 
terminal 3′ sequence. With the exception of the smallest, 
all sgmRNAs are structurally polycistronic and possess the 
genetic information for several proteins. In the majority of 
instances, only the 5′ most proximal ORF is translated and, 
therefore, coronavirus sgmRNAs are functionally monocis-
tronic, although some virus- and gene- specific exceptions do 
occur. In IBV, for example, gene 3 encodes proteins 3a, 3b and 
3c (E), with 3a and 3b translated by leaky ribosomal scanning 
and 3c translated using an internal ribosomal initiation site 
[9].
The process of discontinuous transcription is controlled by 
interactions of both the TRS- L and the TRS- B. The presence 
of a TRS- B upstream of each structural and accessory gene 
is essential for the transcription of the relevant sgmRNA. 
The sequence of the TRSs is largely conserved across the 
coronavirus family and as such it is possible to use a bioin-
formatics approach to screen full genomic sequences to 
identify possible sgmRNAs and subsequent ORFs. For IBV, 
the proposed consensus TRS is CUUAACAA; however, there 
are naturally occurring variations of the TRS- B sequence 
suggesting flexibility and that an exact consensus sequence 
is not an absolute requirement for the TRS- L and TRS- B 
to perfectly match. For example, for the apathogenic strain 
Beaudette and the pathogenic strain M41, the TRS- B for the S 
gene is CUGAACAA. In addition, gene 5 of the M41 strain is 
preceded by a TRS- B of CUUAAUAA, and gene 3 of the Beau-
dette strain utilizes the same sequence as the S gene. Brown et 
al. have also identified variations in putative TRS- Bs of turkey 
coronavirus (TCoV) [10]. The matter is further complicated 
by the presence of functional non- canonical TRS- Bs. Bentley 
et al. identified the presence of a sgmRNA, relating to gene 4b, 
which is transcribed from a shortened non- canonical TRS- B 
of only 3 nucleotides, CAA [6]. This shortened TRS- B was 
found to hybridize to nucleotide positions 6, 7 and 8 of the 
TRS- L, with the remaining TRS in the sgmRNA derived from 
TRS- L. The possibility of IBV generating such transcripts 
was first suggested by Stern and Kennedy in 1980 [11]. Such 
transcripts are not unique to IBV, and have previously been 
described in other coronaviruses including SARS- CoV and 
mouse hepatitis virus (MHV) [12, 13].
Two recent publications have described the detection of a 
non- canonically transcribed sgmRNA in the IBV strain Beau-
dette, located at the very 3′ terminus of the genome, between 
the N gene and the poly(A) tail [7, 14]. Additionally, Dinan 
et al. identified ribosomes bound to the transcript suggesting 
protein translation [7]. The resulting prospective protein in 
the Beaudette strain, however, is prematurely truncated due 
to a single point mutation that results in a premature stop 
codon. In the present study, we similarly describe detection 
of a non- canonically transcribed sgmRNA correlating to the 
3′ extremity of the genome across multiple strains of IBV 
including Beaudette, as well as TCoV. In an effort to study 
potential protein products of the 3′ transcript, we utilized 
a well- established reverse genetics system to generate two 
Beaudette- based rIBVs. The first rIBV has a single nucleo-
tide deletion that removes the premature stop codon, thereby 
allowing a full- length polypeptide comparable to other avian 
coronaviruses to be produced, and the second rIBV contains 
a His- tag added to the N- terminus of this full- length poly-
peptide. In this study we also identified a gene 2- derived 
transcript, denoted 2*, that has previously been reported both 
in IBV [6] and other coronaviruses [15, 16]. We confirmed the 
presence of the internal gene 2 and the 3′ terminal sgmRNAs 
by performing deep- sequence analysis on allantoic fluid 
harvested from IBV- infected embryonated eggs and report 
on the site of leader- body fusions. Our findings highlight the 
potential for further unidentified non- canonically transcribed 
sgmRNAs produced by IBV and further demonstrate the 
potential for coronaviruses to encode an additional repertoire 
of as yet unidentified genes.
METHODS
Cells and viruses
Primary chicken kidney (CK) cells and ex vivo tracheal 
organ cultures (TOCs) were prepared from 2 to 3- week- old 
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specific pathogen free (SPF) Rhode Island Red (RIR) chickens 
as described elsewhere [17, 18]. Continuous cells lines Vero 
and DF1 were provided by the cell culture department at The 
Pirbright Institute. Embryonated RIR hens' eggs at 10 days 
of age were provided by the Poultry Production Unit at The 
Pirbright Institute.
IBV strains M41- CK [19], Beau- R [20] and Beau- CK [21], 
all of the Massachusetts (Mass) serotype, GI-1 lineage [22], 
have been described previously. IBV strain CR88 is used as a 
vaccine against 793B strains, also known as 4/91, which are 
all of the GI-13 lineage [22]. D1466, a member of the GII-1 
lineage first detected in The Netherlands in the late 1970s, was 
a gift from Dr Franz Davelaar of the Doorn Institute, Holland 
[22, 23]. H120 is a widely used vaccine of the Mass serotype, 
GI-1 lineage [22, 24]. Italy-02, a member of the GI-21 lineage 
[22], originated from Italy and was a gift from Professor Elena 
Catelli of the University of Bologna, Italy. The QX strain of the 
GI-19 lineage [22] used in this study was isolated in the UK 
[25, 26] and has since been used to generate a vaccine [27]. 
All isolates of IBV and rIBV were propagated in 10- day- old 
RIR SPF embryonated hens’ eggs. Allantoic fluid was clarified 
by low- speed centrifugation at 24 to 48 h.p.i. (hours post- 
infection) and subsequently assayed to titrate progeny virus 
by plaque assay in CK cells.
Full genome sequencing of viral stocks
As required for 454 pyrosequencing, stocks of each of CR88, 
D1466, H120, QX and Italy-02 were grown in order to obtain 
sufficient purified RNA. To generate these stocks, twenty 
10- day- old embryonated SPF RIR chicken eggs per virus were 
infected with 100 µl IBV- infected allantoic fluid. After 24 h 
incubation, embryos were candled and culled by refrigeration 
for a minimum of 4 h. Allantoic fluid from each viral group 
was pooled and centrifuged to clarify supernatant.
Partial purification of IBV and isolation of viral RNA for deep 
sequencing were performed as previously described [28]. 
Briefly, IBV- infected allantoic fluid was purified by ultracen-
trifugation and the resulting virus pellet was resuspended in 
TRIzol reagent (Invitrogen, Thermo Fisher Scientific). RNA 
was extracted from supernatant as per the manufacturer’s 
instructions and quantified by NanoDrop assay. Samples 
were then sent to the Centre for Genomic Research (CGR), 
University of Liverpool, UK, for library preparation and 
sequencing. cDNA libraries were generated according to the 
GS FLX Titanium cDNA Rapid Library Preparation Method 
Manual [29] and sequenced using a GS FLX with Titanium 
series and run protocol.
The consensus sequence of the 5′ end of the genome for QX, 
D1466, H120, CR88 and Italy-02 was determined from RNA 
extracted from IBV- infected CK cells using a 5′ RACE system 
(Invitrogen by Life Technologies), using IBV- specific primers 
5′-TGTCTGCTCACTAAAC-3′ for the reverse transcription 
step, and 5′-AGAACGTAGCCCAACGC-3′ for the amplifi-
cation of dC- tailed cDNA step. PCR products were cloned 
using a TOPA TA cloning kit for sequencing (Invitrogen by 
Life Technologies), and the sequences of two clones were 
determined per virus. Sanger sequencing was performed by 
Source BioScience, Oxford.
Consensus sequences were assembled for each IBV strain 
using the mira assembler version 3.4.0.1 [30] with genome, 
accurate, 454 and no vector screen settings. Contigs from the 
initial mira assemblies were viewed, edited and ordered as 
necessary, based on known virus consensus sequences using 
the Gap4 and Gap5 programs from the Staden packages 
[31, 32]. The sequences were deposited in GenBank under 
accession numbers MN548285 for CR88, MN548286 for 
D1466, MN548287 for H120, MN548288 for Italy-02 and 
MN548289 for QX.
IBV/rIBV infection of CK cells for intracellular RNA 
preparation
Confluent CK cells in six- well plates (approximately 
1.2×106 cells per well) were washed once with 1x PBS and 
inoculated with 500 µl IBV (at the highest titre possible) 
per well. After incubation at 37 °C for 1 h in 5 % CO2, the 
inoculum was removed and replaced with 3 ml BES (Sigma)- 
containing medium [33]. Infected cells were then further 
incubated until extensive cytopathic effect was observed, 
approximately 24 h.p.i., at 37 °C in 5 % CO2.
IBV/rIBV infection of CK cells for assessment of 
viral growth kinetics
Confluent CK cells, seeded in six- well plates, were infected 
with either 1×104 p.f.u. or 1×105 p.f.u. virus and incubated at 
37 °C for 1 h with 5 % CO2. The inoculum was removed and 
the cells washed twice with 1x PBS, after which 3 ml BES- 
containing medium was added per well. Virus- containing 
supernatant was harvested at 1, 24, 48, 72 and 96 h.p.i., 
and subsequently screened for progeny virus by titration 
in CK cells.
IBV infection of ex vivo TOCs for assessment of 
intracellular RNA or ciliary activity
For the assessment of intracellular RNA, TOCs were 
washed once with 1x PBS and inoculated with 500 µl IBV/
rIBV (at the highest titre possible) per tube in triplicate. 
After incubation at 37 °C for 1 h, 1 ml TOC culture medium 
was added [17]. Infected TOCs were incubated at 37 °C, at 8 
revolutions h−1 for a further 23 h. For TOCs being assessed 
for ciliary activity as described elsewhere [34, 35], incuba-
tion was for a further 95 h, with ciliary activity assessed at 
24 h intervals using an EVOS digital inverted microscope. 
For this assay, TOCs were infected with 1×105 p.f.u. or mock 
infected with medium in replicates of ten.
Preparation of RNA from CK cells, TOCs and 
allantoic fluid
Intracellular RNA was extracted from IBV- infected and 
mock- infected CK cells and ex vivo TOCs at 24 h.p.i. 
using an RNeasy mini kit (Qiagen). The manufacturer′s 
protocol for animal cells, spin with homogenization using 
a TissueLyser II (Qiagen) for 30 s at 25 Hz, was used. RNA 
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was extracted from allantoic fluid using an RNeasy mini kit, 
utilizing the RNA clean- up protocol. All RNA samples were 
stored at −20 °C.
Leader-body junction reverse transcription PCR 
(RT-PCR) analysis
Intracellular RNA was reverse transcribed using Superscript 
III (Life Technologies) with either virus- specific primers 
(Table 1) or random primer 5′- GTTT CCCA GTCA CGAT 
CNNN NNNN NNNNNNNN-3′ (Sigma). The resulting 
cDNA was amplified by PCR using Taq polymerase (Life 
Technologies) with either a universal forward primer (5′- 
CTATTACACTAGCCTTGCGC-3′) or a virus- specific 
primer (Table  1) located in the leader sequence of the 
5′ end of the IBV genome. This was paired with either a 
universal primer (5′- GCTC TAAC TCTA TACT AGCCT-3′) 
or virus- specific primer (Table 1) located at the far 3′ end of 
the genome, directly preceding the poly(A) tail. PCRs were 
performed using a thermal cycler (2720 Thermal Cycler; 
Applied Biosystems) with the following protocol: 95 °C 
for 2 min; followed by 25–35 cycles of 95 °C for 30 s, 49 °C 
for 30 s and 72 °C for 2 min; and a final cycle of 72 °C for 
10 min. PCR products were cloned using either a TOPO TA 
cloning kit for sequencing with a pCR4- TOPO vector or a 
TOPO TA cloning kit with pCR2.1- TOPO vector (both Life 
Technologies). One Shot MAX Efficiency TOP 10 or One 
Shot MAX Efficiency DH5α-T1R chemically competent 
cells (Life Technologies) were used for the transformation 
step. The bacterial colonies produced were screened either 
through PCR using primers M13 forward (5′-GTAAAAC-
GACGGCCAG-3′) and M13 reverse (5′-CAGGAAACAGC-
TATGAC-3′) utilizing the PCR protocol described above 
or through EcoRI (Life Technologies) restriction digest of 
overnight cultures processed using a QIAprep spin mini-
prep kit (Qiagen). Both the plasmid preparations and PCR 
products were sequenced by Source BioScience, Oxford or 
GATC, Germany. Approximately 25–50 colonies from each 
transformation were screened.
Northern blot analysis
mRNA was isolated from intracellular RNA extracted from 
CK cells at 24 h.p.i. using a Poly(A) Purist MAG kit (Ambion), 
following the manufacturer′s protocol. Northern blot analysis 
was carried out using a NothernMax- Gly kit (Ambion). 
Briefly, after denaturation at 50 °C with an equal volume of 
glyoxal loading dye for 30 min, mRNA was separated in a 
1.1 % low- electroendosmosis (LE) agarose gel. The mRNA 
was transferred to a BrightStar- Plus positively charged nylon 
membrane via capillary action for 90 min and cross- linked 
by UV exposure (using the auto crosslink function of a 
Stratalinker UV Cross- linker; Stratagene). The membrane 
was pre- hybridized with ULTRAhyb buffer for 30 min at 
42 °C, before overnight incubation at 42 °C with a DNA 
probe specific for the 3′ end of the genome (forward primer, 
5′-CAACAGCGCCCAAAGAAG-3′, within the N gene 
and reverse primer located in the 3′-UTR, 5′- GCTC TAAC 
TCTA TACT AGCCT-3′). The membrane was washed and the 
blot developed using a BrightStar Biodetect kit (Ambion), 
following the manufacturer′s protocol.
Construction of a plasmid containing modified ORF 
7
The plasmids pGPT- BeauR- ORF7rep and pGPT- BeauR- 
ORF7rep- HIS were generated by GeneArt. Briefly, to 
construct pGPT- BeauR- ORF7rep, gene synthesis was 
carried out generating a sequence relating to Beau- R 
[National Center for Biotechnology Information (NCBI) 
GenBank accession number AY311317] genome positions 
26 714–27 540 with nucleotide T27141 deleted. To construct 
pGPT- BeauR- ORF7rep- HIS, gene synthesis was used to 
generate the above fragment with nucleotides encoding a 
His- Tag comprised of six histidine residues inserted at posi-
tion 27 114 immediately after the start codon, enabling ORF 
7 to express a His- Tag on the N- terminus of the protein. 
This genome segment was then cloned into plasmid pGTP-
 NEB193, which is used as a donor molecule in the IBV 
reverse genetics system [20].
Table 1. Virus- specific primers used to amplify sgmRNA in leader body junction PCR analysis
The forward primer is located in the 5′ leader sequence and the reverse primer in the 3′-UTR.
Virus (strain) Forward primer (5′→3′) Reverse primer (5′→3′)
TCoV CTATCATACTAGCCTTGTGC GCTCTAACTCTATACTAGCCT
Beaudette CTATTACACTAGCCTTGCGC TGCTCTAACTCTATACTAGCC
M41 CTATCACACTAGCCTTGCGC TGCTCTAACTCTATACTAGCC
H120 CTATTGCACTAGCCTTGCGC TTCTCTAACTCTATACTAGCC
Italy-02 CATACACACTAGCCTTGTGC GTCTCTAACTCTATACTAGCC
QX CATACATACTAGCCTTGCGC TGCTCTAACTCTATACTAGCC
CR88 CATACATACTAGCCTTGTGC TGCTCTAACTCTATACTAGCC
D1466 CATACATACTAGCCTTGCGC TTTTTTGACTCTATACTGGCC
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Generation of a recombinant vaccinia virus 
containing modified IBV cDNA and the subsequent 
recovery of infectious IBV
The modified region of the IBV cDNA encoded in plasmids 
pGPT- BeauR- ORF7rep and pGPT- BeauR- ORF7rep- HIS 
were introduced into the full- length IBV cDNA Beau- R held 
within a vaccinia virus genome by homologous recombina-
tion using the transient dominant selection system described 
previously [33, 36, 37]. Infectious rIBVs containing the 
correctly modified sequence were then recovered [20, 33, 37] 
and passaged twice in CK cells. A stock of each rIBV was 
grown in 10- day- old SPF embryonated hens’ eggs, which was 
used for all subsequent experiments.
Deep sequencing of Beau-CK infected allantoic fluid
Beau- CK infected allantoic fluid was harvested and clarified 
by low- speed centrifugation for 10 min. The resulting super-
natant was then subjected to ultracentrifugation at 236 880 g 
for 1 h on a 30 % sucrose gradient and the pellet resuspended 
in 300 µl RLT buffer. Total RNA was then extracted using a 
Qiagen RNeasy kit, following the manufacturer′s protocol. 
RNA was checked for quality using a Bioanalyzer 2100 RNA 
Pico kit (Agilent), quantitated using a Qubit (Life Technolo-
gies) and normalized for a 100 ng input. Sequencing library 
preparation was performed using a NEBNext directional 
Ultra RNA- Seq kit (NEB). Library quality control (QC) was 
performed using the Bioanalyzer 2100 DNA 1000 kit and 
Qubit prior to pooling. The library pool was quantified using 
a NEBNext Illumina library quantitation kit (NEB) before 
being diluted and loaded onto a single lane of an Illumina 
HiSeq 4000.
Analysis of deep sequencing data
Resulting reads were quality assessed using FastQC [38] 
with quality filtering then performed with Trim Galore! 
version 0.6.2 [39] using the following parameters: input as 
paired reads, minimum sequence length=100, quality score 
cut- off=30, trim 15 bp from 5′ end of R1 and R2 read. Host 
subtraction was performed by aligning passed quality filter 
(PQF) reads to the galGal6 reference genome with a de novo 
consensus sequence for Beau- CK generated from non- host 
derived reads using SPAdes. All quality- filtered reads were 
then aligned to the Beau- CK genome using BBMap [40] using 
default parameters. Chimeric reads were identified by initially 
performing an alignment with bwa [41] with reads flagged as 
chimeric exported and subsequently aligned using BBMap. 
PQF reads possessing leader sequence were identified by 
searching for the sequence TTAAAAATCTAGC, the reverse 
complement of GCTAGATTTTTAA, a sequence located 
within leader of Beau- CK at nucleotide positions 44–56 
(NCBI GenBank accession number AY311317). To prevent 
duplicate matches (in forward and reverse reads), read 
pairs were merged using pear (Paired- End reAd mergeR) 
[42] prior to searching. The resulting fasta sequences were 
trimmed to remove the 5′ sequence upstream (relative to the 
viral genome) up to and including the leader search sequence 
and aligned to the Beau- CK reference using bwa. Coverage 
was reported using SAMtools (version 1.4) [43]. Data has 
been deposited in the Sequence Read Archive (SRA), under 
accession number PRJNA577406.
RESULTS
Identification of a putative sgmRNA located 
downstream of the N gene
The analysis of the full- length genome sequences of several 
IBV strains has identified a potential ORF at the 3′ end of the 
genome between the end of N and the poly(A) tail in what 
is considered as a hypervariable region of the IBV 3′-UTR 
[7, 14]. Britton and Cavanagh (in 2008) had previously 
considered an ORF in this area due to the presence of an 
AUG start codon, but discounted the possibility of another 
gene due to the apparent lack of a TRS- B [44]. For the IBV 
strain Beaudette, a canonical TRS- B of either CUUAACAA, 
CUGAACAA or CUUAAUAA cannot be identified in the 
genome between the middle of the N gene and 5′ of the puta-
tive ORF, which raised the possibility that the mechanism of 
transcription was either similar to that of gene 4b [6], which 
uses a shortened non- canonical TRS- B, or that a TRS- B of 
an unidentified sequence was being utilized. To determine 
whether a sgmRNA was produced during IBV infection that 
relates to the 3′ end of the genome, primary CK cells were 
inoculated with the rIBV Beau- R [20]. Northern blot analysis 
of the infected cell lysate identified a potential sgmRNA, 
smaller than the sgmRNA encoding the N protein (Fig. 1a). 
Interestingly, on a 1.1 % agarose gel this smaller putative 
sgmRNA runs in front of the loading dye, so it is likely that it 
had either run off the gel or been removed when the gel was 
trimmed for the RNA transfer process in previous experi-
ments. In addition, the relatively low abundance of the mRNA 
compared to the other sgmRNAs produced by the structural 
and accessory genes raises the possibility that this band has 
previously been assumed to be background and the result of 
non- specific binding, similarly to the way 4b had previously 
been described [6]. In the time that this paper has been in 
preparation, both Dinan et al. (2019) [7] and An et al. (2019) 
[14] have both also identified a potential sgmRNA located 
between the N gene and the 3′-UTR.
Confirmation of the presence of a sgmRNA
To confirm that the IBV- derived RNA observed on the 
Northern blot did relate to a novel IBV sgmRNA, intracel-
lular RNA was extracted from CK cells infected with Beau- R 
or M41- CK. Leader- body junction RT- PCR was then used to 
amplify sgmRNAs. The primer set chosen, forward primer 
(5′- CTATTACACTAGCCTTGCGC-3′) located in the leader 
sequence and reverse primer (5′- GCTC TAAC TCTA TACT 
AGCCT-3′) located upstream of the poly(A) tail, would 
potentially amplify all sgmRNAs present. Due to the nature 
of PCRs, however, smaller templates would be preferentially 
amplified. A PCR product of ~2000 bp was produced from 
both Beau- R and M41- CK infected cells, whilst a PCR 
product of 500–650 bp was consistently produced from 
Beau- R infected cells but not those infected with M41- CK 
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(Fig. 1b). Cloning of the Beaudette- and M41- derived PCR 
products, followed by sequence analysis, confirmed that the 
PCR products related to sgmRNAs due to the presence of the 
IBV leader sequence. Sequence alignments showed that the 
products of around 2000 bp related to the sgmRNA encoding 
the N gene from both M41- CK and Beau- R infected cells. 
The smaller PCR product only derived from Beau- R infected 
cells was found to align to the 3′ end of the genome, with the 
start of the sgmRNA immediately downstream of N (Fig. 1c). 
Interestingly, M41- CK has a 185 nucleotide deletion in this 
region of the 3′-UTR.
Sequence alignment identified that the TRS of the sgmRNA 
did not align with the genome with perfect homology (Fig. 1c). 
However, unlike gene 4b in which only 3 nucleotides (CAA) 
of the TRS of the sgmRNA match the genome sequence [6], 
5 nucleotides (UAACA) matched in the newly identified 
sgmRNA. Therefore, the TRS- B was determined to consist of 
nucleotides UAACA, which align with positions 3 to 7 in the 
TRS- L (Fig. 1c). This finding supports reports by both An et 
al. (2019), who identified a TRS- B of UAACA [14], and Dinan 
et al. (2019), who identified a putative TRS- B of UAACAU [7]. 
Sequence alignment of the 3′-UTR for Beau- R and M41- CK 
identifies that the deletion seen in the latter starts 2 bp into 
the newly identified TRS- B (Fig. 1d), suggesting that the 5 
nucleotides comprising this TRS- B are required for the tran-
scription of the newly identified sgmRNA. Considering the 
Fig. 1. Identification of an mRNA located between N gene and the poly(A) tail for Beau- R but not M41- CK. (a) Northern blot analysis of 
Beau- R infected whole- cell lysate. A clearly distinguishable band, designated 7, is present at the bottom of the gel at relatively low 
abundance. The location of this transcript likely corresponds to the area of the genome between gene 6 (N) and the 3′-UTR. A faint 
band designated as 2* is also observed between genes 2 and 3. (b) Leader- body PCR analysis of Beau- R and M41- CK infected CK cell 
whole- cell lysate. Amplification of sgmRNAs by PCR produces two bands in the instance of Beau- R after separation by agarose gel 
electrophoresis. The larger sized product (~2000 bp) corresponds to the expected band size for gene 6 (N protein) transcripts. A smaller 
product (~500–650 bp) is also produced in Beau- R, but does not occur in M41- CK infected cell lysate. (c) Sequencing of leader- body 
PCR products. Sequencing of this smaller band confirms a match to the 3′ end of the virus genome (Beau- R NCBI GenBank accession 
number AJ311317), but the sequence also possesses a leader sequence corresponding to the 5′ end of the genome and, hence, has 
the characteristics of a sgmRNA. Reads do not confirm an alignment to the TRS with perfect homology and instead match only 5 
nucleotides (TAACA). (d) Pairwise alignment of Beau- R and M41- CK sequences after the N stop codon. An alignment between the Beau- R 
and M41- CK sequences from genome position 27 100–27 607 (relative to Beau- R NCBI GenBank accession number AJ311317) reveals 
a 185 nucleotide deletion in M41- CK versus Beau- R, as well as three single nucleotide polymorphisms (shown in red font). The deletion 
includes part of the prospective TRS- B and the sgmRNA sequence. In (c) and (d), the coloured boxes indicate: red, N stop codon; blue, 
nucleotide matches to the canonical TRS (CTTAACA); green, prospective ORF 7 start codon.
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identification of a functional TRS- B, and the location of the 
ORF that is separate to gene 6 (N gene), the newly identified 
sgmRNA and corresponding ORF will be referred to as gene 
7.
A sgmRNA relating to gene 7 is expressed from 
several IBV strains and TCoV
To establish whether the newly identified sgmRNA was 
specific to the Beaudette strain or was present in other strains 
of IBV, full genome sequencing of five strains of IBV was 
undertaken using 454 pyrosequencing technology. The strains 
investigated included vaccine strains CR88 and H120, as well 
as field isolates D1466, Italy-02 and QX.
Investigation of a variety of both field and vaccine IBV strains 
by leader- body junction RT- PCR and Northern blot analysis 
identified sgmRNA 7 in several other viruses (Fig. 2a, b), 
including the vaccine strains H120 and CR88 and patho-
genic strains D1466, Italy-02 and QX. Leader- body junction 
RT- PCR followed by sequence analysis demonstrated that 
there is variability in the number of nucleotides that constitute 
the TRS- B (Fig. 2c). Both the genomes of Beau- CK and QX 
contain a TRS- B of UAACA, which aligns with nucleotides 
3 to 7 of the TRS- L, CUUAACAA. This also confirms the 
molecular clone Beau- R is comparable to the parental virus 
Beau- CK (Figs 1c and 2c). Unlike the Beaudette strains, the 
TRS- B for CR88 reads UUAACA aligning to positions 2 to 
Fig. 2. A gene 7 transcript is produced by diverse strains of IBV. (a) Leader- body PCR analysis of infected CK cell whole- cell lysate. 
Amplification of sgmRNAs by PCR and subsequent separation by agarose- gel electrophoresis produces two bands in the instance 
of Beau- CK, D1466, QX, H120 and CR88, and three bands in the instance of Italy-02. All six viruses produce bands corresponding 
to gene 6 (N protein,~2000 bp) and gene 7 (~500–600 bp). The larger band in Italy-02 relates to gene 5. (b) Northern blot analysis of 
infected whole- cell lysate. A clearly distinguishable band is present at the bottom of the gel for H120, Beau- R, Beau- CK and CR88 that 
corresponds to sgmRNA 7. Confirmatory to Fig. 1(b), M41- CK does not have a band corresponding with sgmRNA 7. All five viruses have 
bands corresponding to the other sgmRNAs as anticipated. However, there is a consistent pattern of bands between genes 6 and 7 
across the IBVs that cannot be explained. (c) Sequence analysis of leader- body PCR products. All sequences are indicative of sgmRNAs; 
however, the TRS- B and the site of leader- body switch is not consistent. Genome positions for each IBV strain are indicated on the left 
(NCBI GenBank accession numbers: AJ311317, MN548285, MN548286, MN548287, MN548288, MN548289). Beau- CK and QX both have 
a partial match to the canonical 8 nucleotide TRS like Beau- R (TAACA). CR88 has a partial match of 6 nucleotides (TTAACA) versus the 
canonical TRS. Sequencing of D1466 resulted in a fluctuation (orange) as to where the leader- body junction for sgmRNA 7 is situated, but 
possess a TAACA TRS. H120 and Italy-02 possess the canonical 8 nucleotide TRS. The distance between the N stop codon (red) and the 
TRS for gene 7 is longer in H120 and Italy-02 versus the other studied IBVs. Red, N stop codon; blue, nucleotide matches to the canonical 
TRS; green, prospective ORF 7 start codon; orange, single nucleotide difference in D1466 leader/body junction.
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7 of the TRS- L, and the TRS- B in the genomes of Italy-02 
and H120 have the highest sequence homology with the 
TRS- L, differing only at position 8. Interestingly, both H120 
and Italy-02 have leader- like sequence located immediately 
upstream of the TRS- B, resulting in a greater number of 
nucleotides between the N stop codon and the TRS- B than 
the other strains assessed. The pathogenic strain D1466 
also presents a more complex scenario as in this assay two 
populations of sgmRNA 7 were identified. One population 
contains a TRS of CUUAACA, which similarly to Beaudette 
had nucleotides 3–7 matching the TRS- B. The other popula-
tion contained a TRS of CGUAACA, differing at position 2, 
with this nucleotide appearing to be derived from the genome 
sequence at position 27 079, rather than the leader sequence 
at position 37. In the latter population, it appears that the 
recombination event between TRS- L and TRS- B has occurred 
between positions 1 and 2 of the TRS- L, with position 1 of 
the TRS derived from TRS- L and positions 2–7 from the 
genome, TRS- B (Fig. 2c). Despite the variation, all the TRSs 
for the sgmRNA 7, in all the IBV strains assessed, possessed 
a common core sequence (CS) of UAACA, supporting the 
notion that the TRS- B is universally UAACA, and also 
suggesting this could be the minimum requirement for effec-
tive transcription.
The leader- body junction analysis was initially carried out 
using universal primers with RNA extracted from infected CK 
cells. To ensure there was no RT- PCR/priming error, primers 
were re- designed to be strain specific (Table 2). Intracellular 
RNA was then extracted from infected CK cells, embryonated 
eggs and TOCs and the leader- body junction RT- PCRs were 
carried out utilizing the strain- specific primers. The results of 
this analysis matched those results detailed in Fig. 2; there-
fore, demonstrating that the sgmRNA was not an artefact of 
virus replication in cell culture (data not shown).
To determine whether the presence of sgmRNA 7 is poten-
tially common to other gammacoronaviruses, its presence 
in another avian Gammacoronavirus, TCoV, was investi-
gated. Total RNA was extracted from TCoV- infected turkey 
embryos and leader- body junction RT- PCR analysis was 
carried out to confirm the presence of a PCR product that 
related to a sgmRNA located at the 3′ of the genome, after 
the N gene (Fig. 3). Sequence analysis of the TCoV- derived 
PCR products identified a PCR product that was analogous to 
the IBV sgmRNA 7, which contained a leader sequence fused 
to the 3′ end of the TCoV genome via a TRS- B of UAACA.
Determination of the origin of the TRS of the newly 
identified sgmRNA
Two rIBVs were previously constructed in the investigation 
of the sgmRNA 4b: BeauR- l- CTGAACAA, which has a 
U→G point mutation at position 3 in the TRS- L, and BeauR- 
l- CTTAACAT that has the mutation A→U at position 8 [6]. 
Results from the previous work, using the rIBVs, demon-
strated that in the case of gene 4b, positions 1–5 of the TRS 
were derived from the TRS- L and positions 6–8 of the TRS 
Table 2. Quantifying transcript sequence origin for each sgmRNA in Beau- CK
pear- merged reads possessing a leader sequence were subsequently screened for the presence of a TRS. The 5′ end of the read (relative to the 
genome) up to and including the leader sequence was removed from the read and the following 8 nucleotide sequence (matching the length of the 
canonical IBV TRS) was captured. The number of identical 8 nucleotide sequences for each gene was counted with instances occurring at a frequency 
>1 % reported. In gene 2 (S protein), for example, 53.4 % of transcripts possessed a CTTAACAA sequence, whereas 45.5 % possessed a CTGAACAA 
sequence. The difference at position 3 presumably originates from an inconsistent switch point from body to leader as the TRS- L possesses a T and 
genome sequence possesses a G at this site.
sgmRNA
(products)
TRS- L Genome Transcript sequence Instances 
(percentage)
2
(S)
CTTAACAA CTGAACAA CTTAACAA
CTGAACAA
3240 (53.4 %)
2754 (45.4 %)
2* CTTAACAA CCAAACAA CTTAACAA
CTAAACAA
398 (90.7 %)
35 (8.0 %)
3
(3a/3b/E)
CTTAACAA CTGAACAA CTTAACAA
CTGAACAA
1777 (61.5 %)
1099 (38.0 %)
4
(M)
CTTAACAA CTTAACAA CTTAACAA 4148 (99.0 %)
4b
(4b/4 c)
CTTAACAA GTGACCAA CTTAACAA
CTTACCAA
922 (96.0 %)
19 (2.0 %)
5
(5a/5b)
CTTAACAA CTTAACAAAAACTTAACAA CTTAACTTTTTCTTAACAA
-----------CTTAACAA
400 (3.0 %)
12 500 (95.2 %)
6
(N)
CTTAACAA CTTAACAA CTTAACAA 35 826 (99.7 %)
7
(7)
CTTAACAA AGTAACAT CTTAACAT
CGTAACAT
90 (82.6 %)
18 (16.5 %)
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were derived from the TRS- B, with the template switch during 
sgmRNA synthesis occurring between positions 5 and 6.
Leader- body junction analysis on RNA extracted from 
BeauR- l- CTGAACAA infected CK cells for characteriza-
tion of sgmRNA 7 identified the transcript possessed a 
CUGAACU sequence (Fig. 4), confirming that the template 
switch included the TRS- L mutation. This would indicate that 
the template switch occurs after position 3 on the canonical 
TRS. Unfortunately, BeauR- l- CTTAACAT could not be used 
in this study as the nucleotide in position 8 in the TRS- B for 
the sgmRNA 7 is already a U.
Potential protein encoded by the novel ORF
Analysis of the genomes from the IBV strains investigated, 
as well as TCoV, demonstrated a large degree of variability 
in the predicted protein sequences of 73 aa associated with 
sgmRNA 7 (Fig. 5). However, for both Beaudette and D1466, 
the predicted proteins are truncated when compared to 
the putative proteins from the other IBVs and TCoV. The 
Beaudette- encoded peptide consists of 10 aa and the D1466- 
encoded peptide of 53 aa. As previously mentioned, the 
genome of M41 does not encode sgmRNA 7 due to a deletion 
in this part of the genome (Fig. 1). Therefore, it is reasonable 
to assume that any potential protein encoded by sgmRNA 7 
is non- essential for virus replication. Conversely, it is possible 
that expression of the protein may be detrimental to virus 
proliferation in cell culture considering that Beaudette, a virus 
which has been passaged over 300 times in various systems, 
has mutated to result in a severely prematurely terminated 
polypeptide.
Using a reverse genetics system previously described by Casais 
et al. [20], a single nucleotide was deleted in Beau- R in order 
to cause a frameshift removing the associated premature stop 
codon (Fig. 6a). Two rIBVs were produced from independent 
homologous recombination events and independent rescue 
events, denoted BeauR- ORF7rep A and BeauR- ORF7rep 
Fig. 3. A gene 7 transcript is also present in TCoV. (a) Leader- body PCR analysis of European TCoV strain 080385d RNA harvested from 
infected turkey embryos. Separation of PCR- amplified TCoV sgmRNAs by agarose gel electrophoresis produces a ~2000 bp band and 
a~500–600 bp band corresponding to the expected sizes of gene 6 and gene 7, respectively. The gene 7 band has notably reduced 
intensity versus gene 6 as seen in IBV. (b) Sequencing of leader- body PCR products. The TCoV 080385d sequence is available (NCBI 
GenBank accession number KR822424.1); however, the 5′ extremities including the leader sequence have not been fully resolved. A 
sequence comparison versus the TCoV strain MG10 RefSeq (NCBI GenBank accession number NC_010800.1) confirms the smaller 
band matches the 5′ leader TCoV sequence (orange) with this exception of 1 nucleotide (purple). Reads confirm that TCoV 080385d 
gene 7 utilizes a TAACA CS. Red, N stop codon; blue, matches to the canonical CS (CTTAACA); green, prospective ORF 7 start codon; grey, 
ambiguity code (Ns) in sequence; orange, nucleotide matches between TCoV 080385d gene 7 leader sequence and TCoV MG10 NCBI 
RefSeq (NCBI GenBank accession number NC_010800.1); purple, nucleotide mismatches between 080385d gene 7 leader sequence and 
TCoV MG10 NCBI RefSeq NC_010800.1.
Fig. 4. Template switch between the TRS- L and TRS- B occurs between positions 3 and 4 of the TRS- L. Sequence analysis of sgmRNA 
7 transcripts expressed in CK cells infected with rIBV BeauR- l- CTGAACAA. The virus genome sequence is shown at the bottom, the 
sequence of sgmRNA 7 in the middle, and the virus genome leader sequence at the top. TRSs are coloured in blue, with the mutated 
nucleotide at position 3 of the TRS- L coloured in orange. The stop codon for N is highlighted in red and the start codon for ORF 7 in 
green. The sgmRNA 7 includes the G at position 3, which has originated from the leader sequence, indicating that the template switch 
has occurred between positions 3 and 4 of the TRS- L. Genome positions according to NCBI GenBank accession number AJ311317 are 
indicated on the left.
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B, both of which have the potential to express a full- length 
protein of 73 aa (Fig. 5) from sgmRNA 7. In an effort to detect 
this protein, two further viruses were generated, similarly 
from independent lineages, BeauR- ORF7rep- HIS 7 and 
BeauR- ORF7rep- HIS 14, both of which contain a His- Tag 
comprised of six histidine residues located at the N- terminal 
end of the repaired polypeptide. The 5′ end of ORF 7 was 
chosen for the His- tag modification instead of the 3′ end due 
to the proximity of the latter to the secondary RNA structures 
present in the 3′-UTR that regulate RNA synthesis [45–48].
The growth kinetics of both isolates of BeauR- ORF7rep 
and BeauR- ORF7rep- HIS were analysed in CK cells, and 
were found to be comparable to Beau- R (Fig. 6b, c). Of 
note, the titres for BeauR- ORF7- rep B were lower than 
Beau- R at both the 48 and 96 h.p.i. time points (P<0.05; 
Fig.  6b), although the difference in titres was minimal. 
Ex vivo TOCs were infected with BeauR- ORF7rep A and 
BeauR- ORF7rep B, and the ciliary activities assessed over 
a 96 h period in 24 h intervals (Fig. 6d). Both isolates did 
cause ciliostasis similar to the parental virus; however, the 
process appeared to be delayed with lower ciliary activities 
observed for Beau- R in comparison to the two rIBVs at 48 
h.p.i. (P<0.005) (Fig. 6d). The observation that both rIBVs 
could induce ciliostasis alongside the growth kinetic assays 
completed in CK cells indicated that any potential protein 
encoded by ORF 7 is not detrimental to viral replication in 
vitro nor in ex vivo TOCs.
To determine whether both isolates of BeauR- ORF7rep and 
BeauR- ORF7rep- HIS produced modified sgmRNA 7 s for 
potential expression of the ORF 7 protein or His- tagged 
version, total RNA was extracted from infected CK cell 
lysate. Leader- body junction RT- PCR analysis confirmed 
that BeauR- ORF7rep expressed the modified sgmRNA 7; 
however, BeauR- ORF7rep- HIS did not (Fig. 6e). Sanger 
sequence analysis of an RT- PCR product to analyse the 
modified genome, utilizing RNA from the same cell lysate, 
demonstrated that the genome of the BeauR- ORF7rep- HIS 
virus retained the His- Tag modification located at the 5′ end 
of ORF 7. The results of the leader- body junction RT- PCR 
analysis indicate that the His- Tag modification appears 
to prevent the expression of the sgmRNA 7, indicating a 
possible role for sequences flanking the TRS- B in the regu-
lation of sgmRNA expression.
Investigation of a non-canonically transcribed 
sgmRNA within gene 2
Previous work involving Northern blot analysis of CK cells 
infected with the rIBV BeauR-Δ-IR revealed the presence of 
an additional RNA species, denoted 2*, that related to a puta-
tive sgmRNA site located within gene 2 (S) [6]. An investiga-
tion, utilizing leader- body junction RT- PCR analysis of RNA 
extracted from Beau- R and Beau- CK infected CK cells, iden-
tified an RT- PCR product whose sequence contained the IBV 
leader sequence fused to the IBV genome within the S gene, at 
position 21 249 of the genome, via a non- canonical TRS- B of 
AACAA accounting for positions 4 to 8 of the TRS- L (Fig. 7a, 
b). Interestingly the sequence analysis also identified a TRS- 
like sequence of CUUACCA located immediately adjacent to 
the TRS- B (Fig. 7b).
To establish whether other IBV strains were capable of 
expressing sgmRNA 2*, total RNA was extracted from 
CR88, QX, Italy-02, H120, D1466 and M41- CK infected 
CK cell lysates and investigated by leader- body junction 
RT- PCR analysis. No RT- PCR product relating to Beaudette 
sgmRNA 2* was identified for any of the other IBV strains 
(data not shown). Sequence alignment of the IBV genomes, 
corresponding to the Beaudette sgmRNA 2* region, showed 
that all of the other IBV strains investigated, except for 
CR88, did not possess a TRS- B of AACAA (Fig.  7c), 
possibly accounting for the lack of sgmRNA 2* expression. 
Notably, all the other strains, except CR88, contained an 
A to C substitution at position 5 of the Beaudette TRS- B, 
which could suggest that a TRS- B of AACA is not sufficient 
to enable synthesis of sgmRNA 2*. Interestingly, CR88 does 
contain a TRS- B of AACAA, comparable to the Beaudette 
strain; however, despite several attempts by both leader- 
body junction RT- PCR analysis and Northern blot analysis 
an RNA relating to sgmRNA 2* could not be identified 
in CR88 infected cells. Further analysis of the genome 
sequence highlights that whilst CR88 and Beau- R share 
identical TRS- B sequences, there are nucleotide differences 
located in both the immediate 5′ and 3′ flanking regions, 
Fig. 5. Alignment of ORF 7 prospective proteins in different IBV strains and TCoV using MView. Gene 7 sgmRNA sequences were screened 
for the presence of an AUG start codon. A 53–77 aa protein sequence was identified in TCoV and all IBVs with exception to Beau- R, which 
has a highly truncated 10 aa protein sequence. A single T deletion in Beau- R at position 27 141 (BeauR- ORF7rep) results in a frameshift 
mutation and the potential to generate a 73 aa product.
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which may be responsible for why CR88 does not produce 
a sgmRNA 2*.
Detection of Beau-CK transcripts in infected 
allantoic fluid
The identification of up to three non- canonically transcribed 
sgmRNAs, 2*, 4b and 7 from IBV, highlighted the possibility 
for IBV to generate a larger number of yet unidentified gene 
products. In an effort to investigate whether there is poten-
tial for even more sgmRNAs, a HiSeq dataset was generated 
to screen for the presence of additional putative sgmRNAs. 
The HiSeq dataset was generated by HiSeq analysis of allan-
toic fluid harvested from Beau- CK infected SPF embryo-
nated hens' eggs. A total of 185 992 reads aligning to two 
distinct, non- consecutive positions of the genome (termed 
chimeric reads) were identified. Separately, a total of 73 846 
reads possessing the IBV 5′ leader sequence were identified 
after merging quality- filtered reads using pear [42]. Peaks 
in coverage for both chimeric- mapped reads and leader- 
possessing reads correspond to sgmRNAs, with 2 (S), 
Fig. 6. Repairing ORF 7 in Beau- R does not affect viral growth in vitro. (a) Pairwise alignment between Beau- R and BeauR- ORF7rep 
recombinant virus sequences. A single T deletion in Beau- R at position 27 141 (BeauR- ORF7rep) results in a frameshift mutation and 
the potential to generate a 73 aa product. Genome positions according to NCBI GenBank accession number AJ311317 are indicated on 
the left. (b, c) Growth kinetics of Beau- R, BeauR- ORF7rep and BeauR- ORF7rep- HIS viruses in vitro. Confluent CK cells seeded in six- well 
plates were infected with (b) 1×104 p.f.u. or (c) 1×105 p.f.u. At 1, 24, 48, 72 and 96 h.p.i., supernatant was harvested and assessed for 
infectious viral progeny by titration in CK cells. Each value represents the mean of three replicates with error bars representing sem. 
Statistical differences denoted by either * (P<0.05) or ** (P<0.005) were assessed using a two- way ANOVA paired with a Tukey test for 
multiple comparisons. The only differences identified were between Beau- R and BeauR- ORF7rep B at 48 and 96 h.p.i. (d) Ciliary activity 
in ex vivo TOCs. In replicates of ten, ex vivo TOCs were infected with 1×105 p.f.u. of either Beau- R, BeauR- ORF7rep A or BeauR- ORF7rep 
B, or mock infected with medium. Ciliary activity was assessed by light microscope at 24, 48, 72 and 96 h.p.i. Each value represents the 
mean score of ten replicates with error bars representing sem. Statistical differences were assessed using a two- way ANOVA paired 
with a Tukey test for multiple comparisons. All three rIBVs were statistically different to mock infected from 24 to 96 h.p.i. (P<0.05). 
Statistical differences between Beau- R and BeauR- ORF7rep A and Beau- R and BeauR- ORF7rep B are highlighted by *** (P<0.0005) and 
**** (P<0.0001), respectively. No other statistical differences between the rIBVs at any time point were identified. (e) Leader- body PCR 
analysis of virus- infected or mock- infected CK cell whole- cell lysate. Amplification of sgmRNAs by PCR utilizing primer leader 1 and 
93/100 produces two bands after separation by agarose gel electrophoresis. The larger sized product (~2000 bp) corresponds to the 
expected band size for gene 6 (N protein) transcripts and the smaller product (~500–600 bp) for gene 7 transcripts.
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3, 4 (M), 5 and 6 (N) clearly identified. Peaks corresponding 
to the non- canonically transcribed sgmRNAs 2*, 4b and 7 
were also identified (Fig. 8). Additional peaks relating to 
either/both chimeric reads and reads containing the IBV 
5′ leader sequence across the Beaudette genome, including 
some originating within gene 1, indicate the potential for 
previously unidentified sgmRNAs and putative associated 
proteins.
A second analysis was performed on the HiSeq dataset 
assessing the usage of specific TRSs for the known sgmRNAs 
(Table 2). This assessment demonstrated there is fluidity in 
the recombination events between the TRS- Bs and TRS- L, 
with variability in the recombination locations identified. 
The Beaudette sgmRNA 2 (S gene) TRS- B has the sequence 
CUGAACAA, meaning there is a mismatch at position 3 
with the TRS- L, CUUAACAA. HiSeq analysis has shown 
that approximately 50 % of the chimeric reads identified a 
sgmRNA 2 possessing a TRS containing a G at position 3 
and 50 % possess a U. This indicates there is the potential 
for variability in the location of the recombination event 
between two TRSs, with the recombination event between 
the S gene TRS- B and TRS- L occurring between positions 1 
and 2 or 2 and 3 of TRS- B to include the G at position 3 in 
sgmRNA 2. In order to allow the U nucleotide at position 3, 
recombination would need to occur at a point somewhere 
between positions 3 to 8 of TRS- B. A similar occurrence 
was observed, from the HiSeq data, for sgmRNA 3 (gene 
3), which has a TRS- B of CUGAACAA; approximately 60 % 
of the sgmRNAs contain a U at position 3 and ~40 % a G.
The sgmRNAs that utilize non- canonical TRS- Bs also 
demonstrate variable locations of the recombination events 
between the associated TRS- B and TRS- L; however, these 
Fig. 7. Detection of a transcript- like sequence between genes 2 and 3. (a) Leader- body PCR analysis of Beau- R and Beau- CK infected CK 
cell whole- cell lysate. Amplification of sgmRNAs by PCR utilizing primer leader 1 and BG139 produces two bands, one relating to gene 2 
(S) transcripts and the second sgmRNA 2* transcripts. (b) Sequence analysis of leader- body PCR products identifies a TRS- B of AACAA. 
TRSs present in the leader, sgmRNA and the genome are highlighted in blue. Highlighted in red, upstream of the genomic TRS- B, is a 
TRS- like sequence. (c) Genome alignment of Beau- R (AY311317.1) position 21 220 to 21 279 surrounding the TRS- B (highlighted in blue) 
with other IBV strains. A TRS- like sequence is highlighted in red and percentage identity (pid) is indicated for each sequence compared 
to Beau- R. Genome positions for each IBV strain are indicated on the left (NCBI GenBank accession numbers: AJ311317, MN548285, 
MN548286, MN548287, MN548288, MN548289).
Fig. 8. HiSeq analysis confirms the presence of genes 2* and 7, and indicates potential for other transcripts across the genome. 
Sequencing coverage of Beau- CK HiSeq reads to Beau- CK genome using three separate inputs. All reads (passing quality filter) were 
aligned to the Beau- CK using BBMap (blue). Beau- CK reads were also aligned the Beau- CK genome using bwa with reads flagged as 
chimeric subsequently aligned using BBMap (green). Forward and reverse reads were merged using pear and reads possessing the 
leader sequence selected. The 5′ end of the read (relative to the genome) up to and including the leader sequence was removed from the 
read, and the remainder aligned to the genome using bwa (red). The trace for the chimeric read coverage plot (green) indicate positions 
in the genome covered by reads that align in two places, whereas the trace in the leader- matching (red) coverage plot indicates positions 
that are covered by reads that also possess the leader sequence. Coverage peaks occur at sites of known transcripts (2, 3, 4, 4b, 5 and 
6), with additional peaks corresponding to gene 2* and 7 transcripts also identifiable.
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also show a clear preference. For sgmRNA 4b (gene 4b) 
the genome reads GUCACCAA with the TRS- B identi-
fied as CAA. HiSeq analysis showed that the majority of 
sgmRNA 4b contained a TRS of CUUAACAA, but there is 
a very small population,~2 %, that contain CUUACCAA, 
a difference at nucleotide position 5. A similar situation 
was identified with sgmRNA 7,~80 % of sgmRNA- derived 
reads contained a TRS of CUUAACAU and~16 % contained 
CGUAACAU; the TRS- B has been identified to be UAACA. 
This observed plasticity in the location of the recombination 
event observed between the TRS- L and a TRS- B suggests 
that the presence of a fixed sequence TRS- B is not sufficient 
alone to regulate transcription, and that other regulatory 
factors are involved.
DISCUSSION
This work has identified and investigated additional exam-
ples of sgmRNAs transcribed from non- canonical TRS- Bs 
within the gammacoronavirus IBV genome, and further 
highlights the potential for coronavirus genomes to encode 
additional ORFs. Interestingly, whilst sgmRNA 2* and asso-
ciated ORF 2*, are likely to be Beaudette- specific and not a 
shared feature of IBV strains, a similarly located ORF has 
been identified in SARS- CoV and in porcine respiratory 
coronavirus [12, 49, 50].
This report identifies another non- canonically transcribed 
sgmRNA, which like sgmRNA 4b, is seemingly universally 
shared between IBV strains. This sgmRNA, designated 
sgmRNA 7, is transcribed from a non- canonical TRS- B, 
UAACA, and contains a putative ORF located at the 3′ end 
of the genome immediately downstream of the N gene and 
upstream of the 3′-UTR: an area previously reported not 
to encode an ORF due to the lack of apparent TRS- B [51]. 
As this paper was in preparation, two further publications 
have identified this sgmRNA in the Beaudette strain of IBV, 
transcribed from a TRS- B of UAACA or a putative TRS- B of 
UAACAU [7, 14]. However, this report furthers the findings 
of both Dinan et al. [7] and An et al. [14] by (i) confirming 
the TRS- B of UAACA in the Beaudette strain and (ii) iden-
tifying the presence of sgmRNA 7 and associated ORF in 
several other IBV strains, both vaccine and field isolates, 
including CR88 and QX, respectively. Interestingly, there is 
variability in the sequence of the TRS- B between the strains 
of IBV, with the genome of CR88 containing a 6 nucleotide 
TRS- B of UUAACA and Italy-02 a 7 nucleotide TRS- B of 
CUUAACA. Of particular note, An et al. [14] stated that 
H120 did not express sgmRNA 7 due to the lack of a TRS- B 
of UAACA; however, this report has demonstrated that H120 
does transcribe sgmRNA 7, but utilizes an extended TRS- B 
of 7 nucleotides, CUUAACA. The TRS- B is, therefore, only 1 
nucleotide short of being considered a canonical TRS- B and, 
interestingly, immediately upstream of the TRS- B is a leader- 
like sequence, also observed in the Italy-02 genome. We 
also demonstrated that the M41- CK strain does not encode 
sgmRNA 7 due to a 185 nucleotide deletion that removes the 
3′ terminal CA of the TRS- B, as well as the majority of the 
genome sequence encoding the associated ORF.
Further comparison of other Mass serotype strains indicates 
that there is some variability between isolates. Whilst vaccine 
strains H52 and H120 share an identical ORF 7 sequence 
(Fig. 9), other Mass isolates differ in this region. Identical 
to the Beaudette strain, a Mass isolate from 1979 (NCBI 
GenBank accession number FJ904722) contains a single 
nucleotide insertion within ORF 7, which results in a prema-
ture stop codon truncating the polypeptide to 10 aa. Mass 
isolates from 1965, 1972 and 1985 (NCBI GenBank accession 
numbers FJ904720.1, FJ904721 and FJ904723.1) possess a 
shortened TRS of TAA and do not have an AUG start codon, 
like the M41- CK strain used in this study (Fig. 9a). Interest-
ingly, a Mass isolate from 2006 (NCBI GenBank accession 
Fig. 9. The presence of gene 7 varies between strains of the Massachusetts serotype. (a) The nucleotide sequences of different Mass 
strains were compared over the start of gene 7. Red, N stop codon; blue, nucleotide matches to the canonical TRS; green, prospective ORF 
7 start codon. (b) A comparison of the amino acid sequences. NCBI GenBank accession numbers: AJ311317.1, MK728875.1, FJ904720.1, 
FJ904721, FJ904722, FJ904723.1, FJ904713, EU817497.1 and MN548287.
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number FJ904713) contains the TAACA TRS like Beau- CK, 
but encodes a different sgmRNA 7 sequence (Fig. 9b). All of 
these Mass isolates were isolated from broiler chickens with 
clinical signs of disease [52], so the variation in ORF 7 cannot 
be linked to pathogenicity.
In alpha- and betacoronaviruses, each TRS is thought to 
contain a CS that is conserved between the TRS- L and TRS- B. 
Flanking the CS is a number of nucleotides, located at the 5′ 
and 3′ ends of a TRS that varies between TRS- Bs [15, 53]. 
Research has shown that sequence homology between the 
CS- L and CS- B is proportional to the abundance of sgmRNA 
observed [15, 16]. In all the IBV strains assessed in this report, 
sgmRNA 7 would appear to have a CS of UAACA; however, 
this CS is not shared between all the known TRS- Bs in the 
genome. HiSeq data generated from Beau- CK infected 
allantoic fluid identified that only nucleotide A at position 4 
and CA at positions 6 and 7, respectively, of the IBV TRS- L, 
CUUAACAA, are shared (Table 2). As a note, the TRS- B of 
sgmRNA 4b only contains CAA, position 6 to 8 of the TRS- L 
[54], but there is an A nucleotide located at position 4 that 
corresponds with both TRS- L and the body of the genome. 
What is interesting regarding sgmRNA 7 is that nucleotides 
CA at positions 6 and 7 of the TRS- L, CUUAACAA, are those 
that are missing from the TRS- B in the M41- CK genome. This 
perhaps indicates that these nucleotides are required for the 
expression of sgmRNA 7.
Regardless of the dynamics and regulation of transcription, 
there is precedent for a functional accessory gene to be 
located between the N gene and the 3′-UTR, with such genes 
extensively studied in the alphacoronaviruses transmissible 
gastroenteritis virus (TGEV) and feline infectious peritonitis 
virus (FIPV) [55–58], deletion of which does not affect repli-
cation in vitro but does affect pathogenicity in vivo [57, 59]. 
In FIPV, the sgmRNA 7 encodes two proteins 7a and 7b, 
101aa/10 kDa and 207aa/~24 kDa, respectively. Similarly to 
TGEV, it has been demonstrated that the 7ab cluster is essen-
tial for virulence in vivo, but not always for replication in vitro, 
with deletion knock- out viruses able to replicate well in feline 
FCWF cells but not peripheral blood monocytes [56, 58, 60]. 
The function of sgmRNA 7 in IBV, and whether a protein is 
produced from the sgmRNA, remains undetermined. An et 
al. [14] reported that there was no AUG start codon present, 
and concluded that sgmRNA 7 was non- coding [14]. Our 
report contradicts these findings by identifying an AUG start 
codon present in all IBV strains investigated, except for some 
Mass viruses including M41- CK, located 2 nucleotides from 
the 3′ end of the TRS- B. This proximity of the TRS- B to the 
AUG start codon is unusually close; the distances between the 
TRS- B and the AUG in Beau- R for genes 2, 3, 4, 5 and 6 are 
52, 23, 77, 20/6 and 93 nucleotides, respectively.
Dinan et al. [7] have also shown the IBV ORF 7 AUG is 
occupied by ribosomes on RNA isolated from Beau- R 
infected CK cells, indicating that sgmRNA 7 is translated 
[7]. Unfortunately, our efforts to His- Tag the full- length 
Beaudette ORF 7 protein were unsuccessful with the His- Tag 
sequence insertion disrupting the transcription of sgmRNA 
7. Whilst this was disappointing, it has provided evidence of 
the importance of the flanking regions located at the 3′ end 
of this TRS- B. An et al. also demonstrated the importance of 
the 3′ flanking sequence, particularly the sequence AAUGG 
at position 27 110–27 114 [14]. Mutations of this motif to 
UUUCC completely disrupted sgmRNA 7 expression; 
although it must be noted these mutations also disrupted the 
start codon. The His- Tag sequence insertion detailed in this 
report also disrupts the AAUGG motif by trans- locating the 
G at position 27 114 to 27 132 of the genome. RNA modelling 
using the RNAstructure tools webserver version 6.0.1 (2018) 
[61] suggests a change in RNA structure as a consequence of 
the 18 nucleotide His- Tag sequence insertion. RNA struc-
ture has been shown to play a regulatory role in coronavirus 
sgmRNA synthesis and in particular the interaction of distally 
located motifs [53, 62, 63]. It is also likely that flanking regions 
surrounding the TRS- B and/or RNA structure play a role in 
the expression of sgmRNA 2*, as despite the presence of a 
TRS- B, CR88 does not express this sgmRNA, indicating that 
other required regulatory factors are not present or are not 
active within the genome.
To assess whether the IBV genome could potentially encode 
additional undefined ORFs, a HiSeq dataset generated from 
Beau- CK infected allantoic fluid was investigated. This 
analysis highlighted that there are several chimeric RNAs 
consisting of the IBV leader sequence fused to different 
regions throughout IBV genome, including within the 
replicase gene (gene 1), all representing potential sgmRNAs. 
Whether these sequences account for biologically relevant 
sgmRNAs remains an unanswered question; however, this 
is not the first report to identify additional chimeric reads 
through sequencing analysis [64, 65]. Of particular note is 
the investigation of the arterivirus simian haemorrhagic 
fever virus, which identified an additional 51 functional 
TRS- Bs, greatly increasing the number of potential ORFs, 
with a number of the newly identified TRS- Bs located within 
gene 1 [64]. Analysis of this dataset has also highlighted that 
the location of the recombination event between the TRS- L 
and TRS- B is not fixed, which could indicate for the role of 
secondary regulating factors.
In conclusion, this report has provided further evidence for 
the presence of an ORF transcribed from non- canonical 
TRS- B located between the N gene and 3′-UTR in several 
strains of the gammacoronavirus IBV, denoted ORF 7. 
Investigation of the newly identified sgmRNA, as well as the 
investigation of sgmRNA 2*, indicates roles of the 5′ and 
3′ flanking sequences of the TRS- B in the transcription of 
sgmRNAs. The HiSeq data generated in the report also iden-
tifies that there is variation in the location of the recombina-
tion event between the TRS- L and TRS- B, and additionally 
highlights the possibility of the IBV genome encoding further 
ORFs likely transcribed at low frequency from non- canonical 
TRS- Bs. The coronavirus replication cycle is complex and 
not fully understood and it is, therefore, important for future 
research to investigate these novel ORFs transcribed from 
non- canonical TRS- B sequences and to assess their role in 
IBV replication.
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